Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    

3SBIO INC. (ADR)
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2017 3 763 M
EBIT 2017 1 121 M
Net income 2017 891 M
Debt 2017 2 000 M
Yield 2017 0,16%
Sales 2018 5 183 M
EBIT 2018 1 445 M
Net income 2018 1 172 M
Debt 2018 1 369 M
Yield 2018 0,19%
P/E ratio 2017 39,88
P/E ratio 2018 30,52
EV / Sales2017 9,92x
EV / Sales2018 7,08x
Capitalization 35 318 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
03/19Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
01/16 3SBIO INC : China FDA Approves New Once-Weekly Bydureon to Improve Glycemic Cont..
2017 3SBIO : new product approved for clinical trials
2017 3SBIO : Accelerates Expansion of its Global Biologics Platform by Acquiring the ..
2017 3SBIO : Accelerates Expansion of its Global Biologics Platform by Acquiring the ..
2017 3SBIO : forms joint venture to buy CDMO business
2017 3SBIO : Therapure Biopharma Inc. Announces Spin Off and Sale of Contract Develop..
2017 3SBIO : Chinese biopharma 3SBio in $290 million deal for unit of Canada's Therap..
2017 ANNOUNCEMENT (1) MAJOR TRANSACTION A : Formation of joint venture and grant of p..
2017 3SBIO : Accelerates Expansion of its Global Biologics Platform by Acquiring the ..
2017 3SBIO : interim net up 37% to Rmb393m; no div
More news
Sector news : Biopharmaceuticals
01:38p ABLYNX : Largest Ablynx investor would consider improved Novo Nordisk bid
12:27p BTG : U.S. court invalidates Johnson & Johnson cancer drug patent, hitting UK's ..
01/17 TSX ends up as banks lead rally after rate hike
01/17 ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
01/17 EXCLUSIVE : J&J attracts Chinese interest for diabetes business in potential $3-..
More sector news : Biopharmaceuticals
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 13,4  CNY
Spread / Average Target -3,7%
EPS Revisions
Managers
NameTitle
Jing Lou Chairman, President & Chief Executive Officer
Wei hong Xiao Chief Operating Officer
Bo Tan Chief Financial Officer & Executive Director
Zhenping Zhu Chief Scientific Officer
Dong Mei Su Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
3SBIO INC. (ADR)5 635
BIOGEN6.37%71 659
CSL LIMITED0.51%51 198
ALEXION PHARMACEUTICALS4.09%27 810
GRIFOLS SA6.73%20 235
BIOMARIN PHARMACEUTICAL1.20%15 848